Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.
MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.
TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.
“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.
The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.
To read the full press release, please click here.
Source: Mereo BioPharma Group plc